
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health is a well-established home and alternate-site infusion services provider, with a strong balance sheet and portfolio split across acute and chronic therapies. Despite potential risks in the regulated healthcare industry, the company's recent merger with BioScrip and positive core growth projections for the second half of 2026 support a positive long-term outlook for investors.
Bears say
Option Care Health is facing challenges with its patient census due to higher-than-anticipated insurance changes, transitioning therapies, and slower growth in certain specialty therapies. These challenges have resulted in a lower patient census and reduced revenue and gross profit expectations for the company. While management is optimistic about its acute therapy business and investment in advanced practitioner capabilities, the company's exposure to Stelara and its limited impact in the future may hinder growth opportunities. There is also uncertainty in the potential for future catalysts and the current valuation seems fair, leading to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares